Preparations combining calcium and cholecalciferol are commonly used for the prevention and treatment of Vitamin D and calcium deficiency and may serve as a supplement adjunct to specific osteoporosis treatment in patients at risk of such deficiencies. The combined formulation is applied in addressing concurrent hypocalcemia and hypovitaminosis D.

---

What Натекаль Д3 Treats: Main Uses and Benefits

The core therapeutic domains include managing Vitamin D3 and calcium deficiency states and providing supportive therapy for osteoporosis, particularly in postmenopausal women and the elderly. The medication plays a role in managing the symptomatic discomfort associated with chronic mineral deficits, including generalized bone pain, persistent muscle weakness, and fatigue. By supporting the maintenance of these essential nutrient levels, the treatment contributes to greater physical stability and functional comfort.

“The primary benefit lies in supporting stable metabolism and skeletal structure, which is considered relevant for long-term health and mobility.”

Quick Fact: Relief for Deficiency-Related Discomfort

The supplement helps address symptom clusters that create noticeable physiological strain, primarily symptoms related to physical discomfort and symptoms of increased neurological or muscular activity resulting from long-standing mineral deficits. This supportive relief may assist with maintaining functional stability during symptomatic phases.

Who Can and Cannot Use Натекаль Д3?

The population eligibility for using Натекаль Д3 (Calcium Carbonate and Cholecalciferol) is strictly defined by government regulatory documents, focusing on patient health status and age.

Contraindicated Populations

Use is absolutely contraindicated in patients with high existing mineral levels, including hypercalcaemia (high blood calcium), hypercalciuria (high urine calcium), and hypervitaminosis D (excess Vitamin D). The medicine must not be used by individuals with severe renal impairment, a history of nephrolithiasis (kidney stones), or conditions that cause high calcium levels (e.g., myeloma). Contraindication also applies to those with known hypersensitivity to the active ingredients or excipients, such as hydrogenated soya oil.

Age and Conditional Restrictions

The product is intended for Adults and the Elderly. Use is not recommended for children and adolescents.

Conditional use is required for certain populations: patients with mild to moderate renal impairment must use the medicine with careful supervision. Caution is also necessary for patients with sarcoidosis or those who are immobilised.

Pregnancy and Lactation

Use during pregnancy is permitted only to correct a documented deficiency and must remain within label-specified daily intake limits. Use during lactation is generally permitted, considering the infant's total Vitamin D intake.

Interactions with other Medicines and Products

Natecal D3 is a combined product containing calcium carbonate and colecalciferol (Vitamin D3), and its components can interact with various medications and certain foods. Always inform your healthcare provider about all prescription drugs, over-the-counter medicines, and supplements you are taking.

Affecting Absorption of Other Drugs

The calcium in the preparation can reduce the absorption of several medicines. To avoid this interaction, it is often necessary to space the administration times. This includes:

• Tetracycline and Quinolone Antibiotics (e.g., ciprofloxacin, doxycycline)
• Bisphosphonates (used for bone disorders)
• Levothyroxine (thyroid hormones)
• Iron, Zinc, and Strontium Salts

These medicines should generally be taken at least 2–4 hours away from Natecal D3, following a doctor's specific advice.

Affecting Calcium and Vitamin D Levels

Certain medications can alter the metabolism or excretion of calcium and Vitamin D3, potentially leading to increased blood calcium levels (hypercalcemia) or reduced efficacy of Natecal D3:

Interacting Medication Class	Potential Effect	Recommendation
Thiazide Diuretics	Increased risk of hypercalcemia	Close monitoring of blood calcium levels.
Cardiac Glycosides (e.g., digoxin)	Increased toxicity risk from hypercalcemia	Close monitoring, including ECG.
Corticosteroids (e.g., prednisone)	Reduced Vitamin D effect/calcium absorption	May require higher Vitamin D dosage.
Anticonvulsants (e.g., phenytoin)	Reduced Vitamin D effect due to increased metabolism	Monitoring and possible dosage adjustment.

Additionally, bile acid sequestrants (e.g., cholestyramine) and the weight-loss drug orlistat may reduce the absorption of Vitamin D3. Foods containing oxalic acid (e.g., spinach, rhubarb) or phytic acid (e.g., whole cereals) can also inhibit calcium absorption and should be consumed at least two hours apart from Natecal D3.

The action of Natekal D3 is driven by the synergistic effects of two components: elemental calcium and Vitamin D3 (cholecalciferol), primarily exerting an effect on systemic mineral handling processes and the dynamics of bone tissue turnover.

Vitamin D-Mediated Genomic Signaling

This domain involves the metabolism of cholecalciferol into its active hormonal form, calcitriol (1,25-dihydroxycholecalciferol). Calcitriol binds to the Vitamin D Receptor (VDR), a nuclear receptor that regulates the transcription (gene expression) of specific proteins, regulating gene expression within calcium-handling pathways.

Enhancement of Intestinal Calcium Absorption

The core mechanism is the direct increase of calcium uptake from the gastrointestinal tract. The calcitriol-VDR complex increases the synthesis of calcium-binding proteins (like Calbindin) in the intestinal lining. These proteins facilitate the transport of the calcium component (supplied as calcium carbonate) across the cell membrane and into the circulation.

Regulation of Bone Mineralization and Turnover

Through the delivery of calcium substrate and the VDR-mediated effects on bone cells, the drug engages mechanisms that modulate bone remodeling. This action modulates the differential activity of osteoblasts (formation) and osteoclasts (resorption), which influences the incorporation of calcium and phosphate into the bone matrix.

How to Use Натекаль Д3: Official Administration Guidelines

The usage of Натекаль Д3 (Calcium Carbonate 600 mg / Cholecalciferol 400 I.U. chewable tablets) is defined by prescriptive instructions governing the method, frequency, and timing of administration. The route of administration is strictly oral.

---

Standard Labeled Regimen

Category	Official Instruction
Dosing Schedule	One chewable tablet twice a day (e.g., one in the morning and one in the evening).
Preparation	The tablet must be chewed or sucked completely; it is not to be swallowed whole.
Timing with Meals	Administration is preferably after meals.

---

Procedural Constraints

The prescribed regimen must adhere to specific spacing requirements relative to other substances. Intake must be separated by at least two hours from consumption of large amounts of food containing oxalic acid (e.g., spinach) or phytic acid (e.g., whole cereals).

The tablet should be taken at least two hours before or after specific concurrent oral therapies, such as those containing iron, zinc, or thyroid hormones. For drugs like bisphosphonates, a separation of at least three hours is required.

---

Population Rule

For use during pregnancy, the regimen is typically restricted to one chewable tablet per day (corresponding to 600 mg calcium and 400 I.U. Vitamin D3). The standard regimen is for adults and the elderly.

---

Connection to the overall use protocol:

These instructions establish a standardized, twice-daily, oral administration pattern that dictates both the non-swallow method of consumption and the necessary time spacing required for the proper use of the combination supplement. The protocol emphasizes precise scheduling to maximize absorption and ensure consistent delivery of the regulated dosage over the designated long-term course.

Research Evidence / Overview of Studies for Натекаль Д3

---

Evidence for Use as Adjunct Therapy for Osteoporosis and Fracture Risk Reduction

The combination of calcium and Vitamin D3 (cholecalciferol) was studied for its role as supportive therapy alongside other medical treatments for osteoporosis. The research base is extensive, including many Randomized Controlled Trials (RCTs) and large-scale meta-analyses that primarily research examined major clinical outcomes such as the incidence of hip fracture and non-vertebral fractures in older adults.

Findings observed in some large meta-analyses show patterns related to measurements where this combined supplementation was associated with patterns of a lower reported incidence of fractures in specific patient cohorts. Research highlights patterns where observed patterns may be more pronounced in high-risk groups, such as elderly patients living in institutional care settings.

However, the findings were mixed when reviewing research conducted on relatively lower-risk patients who were community-dwelling. Evidence quality varies across studies, and there is also limited information for long-term outcomes regarding the sustained effects, and data for certain fracture types, such as clinical vertebral fractures, remain insufficient compared to hip fractures.

---

Evidence for Use in Correcting Calcium and Vitamin D3 Deficiency

Research has explored the use of this combined supplement in patients with confirmed deficiencies of both calcium and Vitamin D3. Research in this context mainly consists of prospective trials which monitored the status of key biomarkers in the blood, such as Vitamin D (25[OH]D) and Parathyroid Hormone (PTH).

Research highlights changes measured during the study period where patients administered the supplement reported normalization of these key blood biomarkers. These findings describe patterns observed in the studies that indicate that the combined supplement was observed to be associated with correction of the mineral deficit. The combination was also evaluated in studies examining patient-reported outcomes describing perceived discomfort, such as chronic muscle weakness and bone pain.

The evidence is limited primarily because these trials focused on biochemical correction over relatively short-term follow-up durations. Therefore, existing studies provide limited information on the long-term clinical significance of biomarker correction, specifically in the population whose only indication was deficiency.

Common questions about Натекаль Д3 (FAQ)

Q: How long can I take Natekal D3 according to official data?

A: Official regulatory documents describe the use of Natekal D3 as a long-term treatment intended for chronic conditions or deficiencies. The duration of therapy is typically determined by the clinical indication. The official product information specifies that for long-term use, the monitoring of blood calcium levels (serum calcium) and kidney function is generally recommended.

Q: What is the difference between Natekal D3 and plain Vitamin D?

A: Natekal D3 is classified as a combined medicinal product, meaning it contains two active ingredients: Calcium Carbonate and Cholecalciferol (Vitamin D3). This differs from a plain Vitamin D supplement, which contains only cholecalciferol. The Vitamin D3 component in this preparation is included because it is essential for promoting the efficient absorption of calcium from the gastrointestinal tract.

Q: Is Natekal D3 a medicinal product or a dietary supplement (BAD)?

A: In authoritative regulatory sources, Natekal D3 is classified as a medicinal product (a medicine). Its official status is defined by a specific pharmacological code (ATC code A12AX), which reflects its classification within regulated drug registries and its established therapeutic indications.

Q: Can taking Natekal D3 affect my blood test results?

A: The product can affect key laboratory indicators of mineral balance. Taking the medication has been associated with elevated levels of calcium in the blood (hypercalcaemia) and calcium in the urine (hypercalciuria). These are key laboratory values that regulatory information indicates may require monitoring during long-term use.

Q: What are the signs of Natekal D3 overdose?

A: Symptoms of overdose are related to elevated calcium levels, a condition known as hypercalcaemia. Signs reported in regulatory documents may include general malaise, such as anorexia, intense thirst, nausea, and vomiting. Other associated signs can include constipation, muscle weakness, and pronounced fatigue.

Q: What is 'hypercalcaemia' and how is it related to Natekal D3?

A: Hypercalcaemia is a medical condition defined as an abnormally high concentration of calcium in the blood. Natekal D3 can cause this condition as an official adverse reaction. This condition is officially noted as being associated with prolonged use or with intake exceeding the prescribed dosage.

Q: How is Natekal D3 described in the register of medicinal products?

A: According to official regulatory registries, Natekal D3 is formally classified as a combination preparation. It falls under the specific pharmacological group designated as Calcium preparations in combination with Vitamin D and/or other agents (ATC code A12AX). This classification summarizes its dual-component formulation and primary therapeutic purpose.

Q: What is meant by 'individual intolerance' in the context of Natekal D3?

A: The official product documentation lists hypersensitivity or intolerance as a reason for not using the product (a contraindication). This refers to the potential for adverse reactions to the active substances (Calcium Carbonate or Cholecalciferol) or any of the excipients (inactive ingredients), such as lactose monohydrate or hydrogenated soya oil.

Q: Does Natekal D3 affect the absorption of zinc or magnesium?

A: Official interaction documents state that calcium-containing preparations can reduce the absorption of zinc salts, which regulatory documents indicate may require the separation of administration times. Additionally, the Vitamin D3 component in the preparation may potentially contribute to increased magnesium levels in the blood, which is noted as a consideration for patients with reduced kidney function.

Q: Do I need blood tests before starting Natekal D3 according to general recommendations?

A: The product is officially indicated for correcting documented deficiencies in calcium and Vitamin D. While official documents do not mandate testing for all patients before beginning treatment, the regulatory information highlights the necessity of regular monitoring of calcium levels and kidney function during long-term use or in specific patient populations.

Q: Does Natekal D3 contain lactose or sugar?

A: Yes, the official list of excipients confirms that the product contains various forms of sugars. These include lactose monohydrate and sucrose. The preparation also contains the sweetener aspartame.

Q: Can Natekal D3 be taken if I have diabetes?

A: Diabetes is not listed as a contraindication in the official product labeling. However, the preparation contains forms of sugars (sucrose and lactose monohydrate) as well as the sweetener aspartame. Official information indicates that these components may need to be considered by patients with diabetes.

Q: Is there a section in the official instructions on the effect on the ability to drive?

A: Yes, the regulatory documentation contains a specific section addressing this topic. Official information indicates that Natekal D3 does not affect the ability to drive or operate machinery that requires high levels of concentration or attention.

Q: What should I do if I miss a dose of Natekal D3, according to general recommendations?

A: According to general dosing protocols found in patient information leaflets, if a dose is forgotten, the advice is to take the tablet as soon as it is remembered. If it is already close to the time for the next scheduled dose, the advice is generally to skip the forgotten dose and continue with the regular schedule. It is specified not to take a double dose to make up for the missed one.

How to Store and Dispose of Натекаль Д3

The official labeling for Натекаль Д3 (Natecal D3) defines specific conditions for storage and disposal, focusing on product stability and safety.

---

Storage Conditions and Stability

Requirement	Status
Temperature	Does not require any special temperature conditions.
Protection	Must be stored in the original package to protect from moisture.
Child Safety	Must be kept out of the sight and reach of children.
In-Use Shelf Life	60 days after first opening the container.

---

Disposal Instructions

To discard expired or unused medicine, do not throw it away via wastewater or household waste. Official regulatory guidance requires consulting a pharmacist on how to properly dispose of the medicine. These measures are necessary to help protect the environment from medicinal waste.